1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
Follow Ming Zhao: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC Tislelizumab, Ablation - Recurrent Hepatocellular Carcinoma | Phase 2 | Unknown | Ming Zhao | 120 | 2020-12-21 | 2023-03-22 |
tislelizumab (1)
China (1)